PCSK9 Inhibitor

BOSTON — PCSK9 inhibition before primary PCI for STEMI, on top of standard statin therapy, significantly lowered LDL at 6 weeks compared with sham control, according to the results of the EPIC-STEMI trial presented at TCT 2022.

BOSTON — In the Healio video exclusive, Roxana Mehran, MD, discussed late-breaking research presented at TCT 2022, as well as the benefits of convening the meeting in person following the COVID-19 pandemic.

Data from an open-label extension of the FOURIER study show use of the PCSK9 inhibitor evolocumab for more than 7 years led to durable reductions in LDL and a reduction in CV events, including CV death, according to a speaker.

The American College of Cardiology issued an expert consensus decision pathway to address new lipid-lowering agents and other developments since the release of the ACC/American Heart Association cholesterol guidelines in 2018.

A recent study found that PCSK9 inhibition did not affect cognitive function or dementia risk.

Data from a genetics-based study show PCSK9 inhibition does not affect cognition function or dementia risk; however, statin use may be associated with some impaired cognitive performance that is outweighed by any CV benefits.

The National Lipid Association updated its scientific statement on statin intolerance with a revised definition of statin intolerance and new guidance on how to manage patients with true or partial statin intolerance.

Zetia and proprotein convertase subtilisin/kexin type 9 inhibitors may reduce nonfatal myocardial infarction and stroke in adults with high or very high cardiovascular risk, according to findings published in The BMJ.

Duration of LDL-lowering therapy had a cumulatively beneficial effect on CV outcomes, according to a meta-analysis of 21 randomized clinical trials published in Circulation: Cardiovascular Quality and Outcomes.

Healio and Cardiology Today have aggregated the top headlines from the 2021 American Heart Association Scientific Sessions.